JP2019521990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521990A5 JP2019521990A5 JP2018565845A JP2018565845A JP2019521990A5 JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5 JP 2018565845 A JP2018565845 A JP 2018565845A JP 2018565845 A JP2018565845 A JP 2018565845A JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- item
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 43
- 239000000725 suspension Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 229960002833 aflibercept Drugs 0.000 claims description 15
- 108010081667 aflibercept Proteins 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 12
- 201000011190 diabetic macular edema Diseases 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 239000013646 rAAV2 vector Substances 0.000 claims description 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940066429 octoxynol Drugs 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351234P | 2016-06-16 | 2016-06-16 | |
| US62/351,234 | 2016-06-16 | ||
| PCT/US2017/038003 WO2017218974A2 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155475A Division JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521990A JP2019521990A (ja) | 2019-08-08 |
| JP2019521990A5 true JP2019521990A5 (enExample) | 2020-07-02 |
| JP6814822B2 JP6814822B2 (ja) | 2021-01-20 |
Family
ID=60663653
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565845A Active JP6814822B2 (ja) | 2016-06-16 | 2017-06-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2020155475A Withdrawn JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2022113865A Pending JP2022137244A (ja) | 2016-06-16 | 2022-07-15 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2024095160A Pending JP2024113193A (ja) | 2016-06-16 | 2024-06-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155475A Withdrawn JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2022113865A Pending JP2022137244A (ja) | 2016-06-16 | 2022-07-15 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2024095160A Pending JP2024113193A (ja) | 2016-06-16 | 2024-06-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20190151409A1 (enExample) |
| EP (2) | EP3795181B1 (enExample) |
| JP (4) | JP6814822B2 (enExample) |
| KR (2) | KR20210021113A (enExample) |
| CN (2) | CN109641065A (enExample) |
| AU (3) | AU2017286673B2 (enExample) |
| BR (1) | BR112018076124A2 (enExample) |
| CA (1) | CA3027737A1 (enExample) |
| CY (1) | CY1123697T1 (enExample) |
| DK (2) | DK3795181T3 (enExample) |
| ES (1) | ES2840059T3 (enExample) |
| FI (1) | FI3795181T3 (enExample) |
| HR (1) | HRP20201842T1 (enExample) |
| HU (1) | HUE051953T2 (enExample) |
| IL (3) | IL279919B2 (enExample) |
| LT (1) | LT3471780T (enExample) |
| MX (2) | MX391779B (enExample) |
| PT (2) | PT3795181T (enExample) |
| RS (2) | RS67328B1 (enExample) |
| SG (1) | SG11201811232XA (enExample) |
| SI (2) | SI3795181T1 (enExample) |
| SM (2) | SMT202100010T1 (enExample) |
| WO (1) | WO2017218974A2 (enExample) |
| ZA (1) | ZA201808538B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102288849B1 (ko) | 2014-03-17 | 2021-08-12 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| HUE051953T2 (hu) * | 2016-06-16 | 2021-04-28 | Adverum Biotechnologies Inc | Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával |
| US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| EP4653536A2 (en) | 2017-03-17 | 2025-11-26 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| AU2018372235B9 (en) * | 2017-11-27 | 2022-03-10 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| WO2019198084A1 (en) * | 2018-04-12 | 2019-10-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| NZ770284A (en) | 2018-05-10 | 2025-11-28 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| US20200297869A1 (en) * | 2019-03-04 | 2020-09-24 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
| BR112021021156A2 (pt) * | 2019-04-24 | 2022-02-08 | Regenxbio Inc | Terapêuticos anticorpos totalmente humanos pós-tradução modificados |
| WO2021050649A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| MX2022002960A (es) * | 2019-09-11 | 2022-04-06 | Adverum Biotechnologies Inc | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. |
| TWI819268B (zh) * | 2020-01-16 | 2023-10-21 | 詹姆斯 Ｗ 希爾 | 藉由基因轉導改變眼睛顏色 |
| FR3111913A1 (fr) * | 2020-06-30 | 2021-12-31 | Eyevensys | Construction d’adn pour le traitement de pathologies oculaires |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| AU2021313839A1 (en) * | 2020-07-21 | 2023-03-23 | FTGEN Corp | Composition and method for treating eye diseases |
| CN113817775B (zh) * | 2020-08-25 | 2023-02-17 | 南京吉迈生物技术有限公司 | 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用 |
| MX2023002695A (es) * | 2020-09-03 | 2023-05-19 | Univ Massachusetts | Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2021049374A (ja) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | 遊技機 |
| CA3215855A1 (en) * | 2021-04-27 | 2022-11-03 | Julie Clark | Methods of treating ocular diseases using aav2 variants encoding aflibercept |
| WO2023155918A1 (zh) | 2022-02-21 | 2023-08-24 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| WO2025072688A2 (en) * | 2023-09-27 | 2025-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66184B1 (sr) * | 2011-04-22 | 2024-12-31 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
| US10568934B2 (en) * | 2012-05-07 | 2020-02-25 | Allergan, Inc. | Method of treating AMD in patients refractory to anti-VEGF therapy |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| WO2013188316A1 (en) * | 2012-06-11 | 2013-12-19 | Avalanche Biotechnologies, Inc. | Optical regulation of gene expression in the retina |
| MX2016000364A (es) * | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Metodos para tratar o prevenir afecciones oftalmologicas. |
| JP6607850B2 (ja) | 2013-10-18 | 2019-11-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 |
| KR20170137730A (ko) * | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| HUE051953T2 (hu) * | 2016-06-16 | 2021-04-28 | Adverum Biotechnologies Inc | Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával |
-
2017
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 RS RS20251055A patent/RS67328B1/sr unknown
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 PT PT201966579T patent/PT3795181T/pt unknown
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt unknown
- 2017-06-16 SM SM20210010T patent/SMT202100010T1/it unknown
- 2017-06-16 FI FIEP20196657.9T patent/FI3795181T3/fi active
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en not_active Ceased
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Ceased
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 DK DK20196657.9T patent/DK3795181T3/da active
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2017-06-16 IL IL279919A patent/IL279919B2/en unknown
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 SM SM20250400T patent/SMT202500400T1/it unknown
- 2017-06-16 SI SI201731629T patent/SI3795181T1/sl unknown
- 2017-06-16 MX MX2018015512A patent/MX391779B/es unknown
- 2017-06-16 IL IL314568A patent/IL314568B2/en unknown
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 EP EP20196657.9A patent/EP3795181B1/en active Active
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active Active
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
-
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
-
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
-
2021
- 2021-09-01 AU AU2021225178A patent/AU2021225178B2/en active Active
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
-
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
-
2025
- 2025-04-28 AU AU2025202930A patent/AU2025202930A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521990A5 (enExample) | ||
| JP2019521989A5 (enExample) | ||
| HRP20201842T1 (hr) | Liječenje amd korištenjem aav2 varijante s afliberceptom | |
| HRP20220612T1 (hr) | Sastavi i metode za smanjenje očne neovaskularizacije | |
| Yoon et al. | Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I | |
| Pan et al. | Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice | |
| Barnett et al. | Complications of retinopathy of prematurity treatment | |
| CN108368165A (zh) | 用于治疗颅内出血相关症状的方法和组合物 | |
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2025537601A (ja) | 組換えアデノ随伴ウイルスベクターの薬学的組成物及びその適用 | |
| JP2018527941A5 (enExample) | ||
| JP2020510648A5 (enExample) | ||
| JP2018509154A5 (enExample) | ||
| US20200147187A1 (en) | Compositions and methods for treating neonatal biliary atresia | |
| CN117180455A (zh) | 腺相关病毒药物组合物及其用途 | |
| KR20230004752A (ko) | 척수성 근위축증의 치료 방법 및 약물 | |
| JP2023515916A (ja) | 神経損傷及び関連障害を治療するための方法 | |
| Aziz et al. | Review of gene therapy clinical trials for retinal diseases | |
| US20180000892A1 (en) | Methods and pharmaceutical compositions for the treatment of ischemic conditions | |
| CN119909180A (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 | |
| CN118831152A (zh) | 导管素抗菌肽在缺血性脑卒中药物中的应用 | |
| Ratra | Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema | |
| JP7616697B2 (ja) | ウイルス性肺炎を治療する方法及び薬剤 | |
| NZ749897B2 (en) | Treatment of amd using aav2 variant with aflibercept | |
| NZ749897A (en) | Treatment of amd using aav2 variant with aflibercept |